Company Performance Metrics
Richard Ganz: Chairman & Board of DirectorsPast Role: Piramal Critical Care, Chief Operating Officer
Allen Nissenson: Chief Medical OfficerPast Role: University of California, Los Angeles, Associate Dean
Sentien Biotechnologies is a privately-owned, clinical-stage company developing novel cell therapies that restore balance to the immune system and transform treatment options for patients with systemic inflammatory diseases. The company's innovative blood conditioning approach has been proven to significantly enhance exposure and extend
therapeutic activity of Mesenchymal Stromal Cells (MSCs). By immobilizing MSCs in an extracorporeal device, their flagship SBI-101 product enables sustained, controlled dosage of secreted anti-inflammatory and regenerative properties that are unattainable by direct injection or intravenous infusion.
Sentien Biotechnologies was established in 2008 and is headquartered in Lexington, Massachusetts, United States.
